Loading...
XSHE
002728
Market cap946mUSD
Dec 05, Last price  
13.05CNY
1D
-1.66%
1Q
46.79%
Jan 2017
-31.89%
IPO
64.77%
Name

Teyi Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002728 chart
P/E
326.65
P/S
9.73
EPS
0.04
Div Yield, %
5.36%
Shrs. gr., 5y
12.35%
Rev. gr., 5y
-5.67%
Revenues
688m
-35.55%
202,139,105250,807,519305,131,322340,827,193342,720,955344,748,357516,540,038655,856,830686,943,602884,975,624921,122,276632,695,186758,160,497886,570,9381,067,212,109687,785,167
Net income
20m
-91.90%
24,099,88347,984,75169,694,93478,578,10480,554,67880,193,67381,105,34294,777,036106,342,795155,546,465171,710,43143,816,477126,917,422178,204,104253,175,78920,495,003
CFO
-23m
L
22,315,50146,915,76069,806,575104,502,75074,229,58857,348,29668,867,455101,296,691102,956,107187,969,540221,644,491168,985,866256,814,750371,658,160198,557,705-22,549,753
Dividend
Apr 24, 20240.7 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Teyi Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical preparations, raw materials, and products in China. The company offers cough and phlegm, kidney, anti- infection, cardiovascular, and digestive system drugs. Its chemical raw materials and products include aluminum magnesium carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co., Ltd. in November 2016. Teyi Pharmaceutical Group Co., Ltd. is based in Taishan, China.
IPO date
Jul 31, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT